A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

Trial Profile

A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Beta-thalassaemia
  • Focus Therapeutic Use
  • Acronyms CENTAurus
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 02 Jun 2014 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 02 Jun 2014 Planned initiation date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top